A new Australian study finds that the visual hallucinations sometimes experienced by patients with macular degeneration (MD) may be linked to abnormally heightened activity in the visual cortex of the brain.

Macular degeneration is a retinal eye disease that causes progressive deterioration of the central region of the retina, leading to visual loss in the center of one’s field of vision, while peripheral vision usually remains unaffected. MD is a leading cause of legal blindness in people over the age of 40.

Curiously, many MD patients go on to develop a condition known as Charles Bonnet Syndrome, in which they experience hallucinations as the brain adjusts to significant vision loss. These hallucinations can manifest as simple geometric patterns or much more complex scenes involving animals, people and places.

Why some MD patients experience hallucinations while others do not has remained unclear, but it has been suggested that the activity levels, or excitability, of certain visual regions of the brain may play a role.

In the new study, a research team from The University of Queensland’s Brain Institute and the School of Psychology stimulated the peripheral visual fields of study participants and found that individuals with hallucinations do indeed show significantly heightened activity in particular parts of their visual system.

The researchers used electroencephalography (EEG) to measure brain electrical activity in three groups: a group with macular degeneration and Charles Bonnet hallucinations, a group with macular degeneration and no hallucinations, and a control group of visually-healthy elderly people.

The participants were asked to look at letters appearing on the screen in their periphery while the researchers flashed checkerboards at unique frequencies on the screen. The checkerboards produced unusual oscillations in visual areas of the brain that could be measured using mathematical techniques.

“The main finding is that when we drive activity in the visual system of people with macular degeneration who report experiencing hallucinations, there is a huge visual response compared with participants who have the same visual loss but don’t have the hallucinations,” said first author Dr. David Painter.

Painter noted that while MD patients who experience hallucinations demonstrated visual hyperexcitability, the translation of this hyperexcitability into hallucinations was not automatic and is dependent on external triggers which are still not known.

“During the testing, none of our participants experienced hallucinations, so it’s not that heightened excitability of the brain produces hallucinations — it’s some other factor,” Painter said.

“Sometimes people have these hallucinations when they’re in periods of low sensory stimulation, such as in low-light or periods of inactivity, but for others it can be triggered by things such as car rides or television — it varies for the individual.”

“What our results say is that the brains of those reporting hallucinations are more excitable, but it still remains unclear how that excitability is then translated into hallucinations — that’s a question for future research.”

The findings could help reduce misdiagnosis of hallucinations in people with MD.

“When people get older and they start having these unusual experiences, they are often worried that something is wrong with them, such as dementia or something similar, so they tend to not report the hallucinations for fear they may be treated differently,” Painter said.

“Doctors sometimes don’t recognise the disease either, and therefore can give people inappropriate medication; but our method potentially allows us to detect people who might have Charles Bonnet Syndrome by looking at their brain excitability in response to flickering stimuli.”

The findings are published in the journal Current Biology.

Source: University of Queensland